Product liability claims against Novo Nordisk rest on several established legal theories: Failure to warn patients and healthcare providers about the risk of gastroparesis despite evidence suggesting Novo Nordisk knew or should have known about this severe complication Inadequate labeling that minimized the severity and permanence of gastrointestinal side effects Defective warnings that failed to communicate the risk of NAION and permanent vision loss to prescribing physicians Negligent testing and post-market surveillance that should have detected these patterns of serious adverse events earlier Breach of implied warranty that the medication was safe for its intended use when prescribed as directed The FDAs regulatory timeline supports plaintiff allegations that warnings came too late
Study 5: Hay 2015, review article on amylin biology Citation: Hay D.L., Chen S., Lutz T.A., et al
Example payment for x 3 0% interest, zero fees
Association of BMI with Erectile Dysfunction: A Cross-Sectional Study of Men from an Andrology Clinic. Frontiers in Endocrinology, vol
Whether the medication is covered depends on your specific plan, how the drug is prescribed, and whether you meet strict clinical requirements
This medication is currently available for delivery to the following States: Alaska, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Michigan, Minnesota, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Texas, Utah, Virginia, and West Virginia
